Q/C Technologies, Inc.
- Last sale
- Nov 9, 2026 · +6.10%
- Market cap
- $3.19M
- 8.5M shares
- Filings
- 606
Q2 2020−5.3% FY19 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+470.0% FY25 yoy
- $3.19M
- —
- —
- 0.2×
- -338.53%
- —
FY2025 figures · derived
Price
Nov 9, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2019 | 2019-12-31 | $1,577,033 | reported | |
| FY 2018 | 2018-12-31 | $1,665,570 | reported | |
| FY 2017 | 2017-12-31 | $3,354,712 revised | reported | |
| FY 2016 | 2016-12-31 | $2,960,912 | reported | |
| FY 2015 | 2015-12-31 | $2,115,050 | reported | |
| FY 2014 | 2014-12-31 | $4,427,174 | reported | |
| FY 2013 | 2013-12-31 | $3,577,851 | reported |
In vitro & in vivo diagnostic substances
Q/C Technologies, Inc. is the 18th largest of the 20 covered companies the SEC files under this code, by market cap. SIC 2835
CompanyRevenueGrowthNet marginMarket cap
ICCCImmucell Corp$27.6M4.3%3.8%$89.6MIMDXInsight Molecular Diagnostics Inc.$4.1M115.6%1,238.5%$75.3MAWHLAspira Women's Health Inc.$9.2M0.4%138.7%$16.3MNYMXFNymox Pharmaceutical CorpFiscal 2024 figures———$12.2MVNRXVolitionrx Ltd$1.7M40.0%1,352.2%$6.7MBMRABiomerica Inc$4.5M16.2%84.8%$5.9MCDIOCardio Diagnostics Holdings, Inc.$14.8K57.5%43,832.5%$5.6M
QCLSQ/C Technologies, Inc. (this company)———$3.2M
VRAXVirax Biolabs Group LtdFiscal 2025 figures———$394.7KPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Q/C Technologies, Inc. · CIK 1321834 · Engraved from SEC EDGAR